Log in

Tracker

Reverse merger and M&A tracker

Reverse mergers, takeovers, tender offers, asset sales and control changes at public biotech companies, newest first, with the ownership split where the filing gives it.

Updated October 31, 2026. 260 entries. Download as CSV. Free to cite with a link to this page. All trackers.

DateCompanyTypeWhat happened
InMed Pharmaceuticals INMOther dealInMed sets November 5 record date for CVRs tied to Mentari merger
Rallybio RLYBOther dealRallybio declares estimated $82.7 million cash distribution tied to Avenzo merger
Skye Bioscience SKYEOther dealSkye Bioscience files preliminary proxy for its Redx Pharma acquisition
Bolt Biotherapeutics BOLTReverse mergerBolt Biotherapeutics buys Prana Therapies and raises $120 million
Reverse mergerBiotech reverse mergers reach highest count since 2021 as PIPEs return, J.P. Morgan says
Silence Therapeutics SLNTakeoverMerck KGaA agrees to buy Silence Therapeutics for $20 per ADS to get PV drug divesiran
MiMedx Group MDXGDeal endedMiMedx and Sanara MedTech receive FTC Second Request on merger
MiMedx Group MDXGDeal endedMiMedx and Sanara receive FTC Second Request on proposed merger
Rallybio RLYBReverse mergerRallybio holders to own 2.8% of the combined company in Avenzo reverse merger
Aditxt ADTXDeal endedAditxt unit Ignite Proteomics and Copley Acquisition Corp end SPAC merger deal
AIBOTICS, INC. AIBTOther dealAibotics completes purchase of PlayJamaica robotics and drone assets
Eton Pharmaceuticals ETONOther dealEton Pharmaceuticals pays $10.0 million upfront for US rights to Aquestive's Libervant
LogicMark LGMKOther dealLogicMark completes merger, holders receive $1.31 a share in cash
Pulmatrix PULMOther dealPulmatrix stockholders to vote October 26, 2026 on Eos SENOLYTIX merger
Senti Biosciences Holdings SNTIOther dealSenti Biosciences adjourns annual meeting to seek more votes for merger proposal
Alaunos Therapeutics TCRTOther dealAlaunos Therapeutics acquires Velaris, closes $350 million private placement
Passage Bio PASGReverse mergerPassage Bio holders would keep about 6% in Remix reverse merger, vote Nov 5
Boundless Bio BOLDOther dealBoundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data
Pacira BioSciences, Viatris PCRXVTRSTakeoverViatris agrees to acquire Pacira BioSciences for $36.50 per share in cash
Jasper Therapeutics JSPROther dealJasper Therapeutics offers $0.324 per warrant to buy back up to 12,345,707 warrants
Hepion Pharmaceuticals HEPAOther dealHepion acquires Gravitas Life Sciences in a related party deal
Adia Med ADIAOther dealAdia Med agrees to sell 30% of Adia Labs to QCM Biologics for $1,500,000
BeyondSpring BYSIAsset sale or purchaseBeyondSpring completes sale of subsidiary holding China unit Bulin for non-cash consideration
BeyondSpring BYSIAsset sale or purchaseBeyondSpring sells BeyondSpring Ltd. for trial data rights instead of cash
ENDRA Life Sciences NDRADeal endedENDRA amends merger agreement with ASP Isotopes and Renergen
SpyGlass Pharma, Santen Pharmaceutical Co. SGP4536BLCOAsset sale or purchaseSpyGlass buys lens maker Advanced Vision Science from Santen for about $13 million
Mangoceuticals MGRXOther dealMangoceuticals unit MangoRx IP gets $2.5 million commitment, receives $1.75 million
Chemomab Therapeutics CMMBDeal endedChemomab amends domestication merger terms ahead of Scipher Medicine deal
Lexeo Therapeutics LXEOOther dealLexeo completes Mantle Therapeutics deal for $5,300,000 cash plus $3,000,000 in stock
Lifecore Biomedical LFCROther dealLifecore Biomedical agrees to $6.28 a share cash sale to Webster Equity Partners
Glucotrack GCTKOther dealGlucotrack CEO outlines Lokahi priorities for LT-100 and the ai² platform
Zymeworks ZYMEOther dealZymeworks completes Theravance Biopharma acquisition, with $350 million in senior secured notes
Impact BioMedical, ProPhase Labs IBOPRPHOther dealImpact BioMedical reports Zoar F-4 filing in business combination
AETHLON MEDICAL INC AEMDOther dealAethlon to merge with North Immunology in an all-stock deal
Tarsus Pharmaceuticals TARSOther dealTarsus Pharmaceuticals completes Alkeus acquisition with $270,000,000 in cash up front
iSpecimen ISPCTakeoveriSpecimen agrees to buy Foldlab AI software assets for $4,500,000
Clearmind Medicine CMNDTakeoverClearmind Medicine agrees to buy 51% of Charging Robotics for $2.5 million
International Stem Cell CORP ISCOAsset sale or purchaseInternational Stem Cell completes sale of Lifeline Cell Technology to ATCC
Korsana Biosciences KRSAOther dealCyclerion (now Korsana Biosciences) shareholders approve merger issuance and 1-for-7 reverse split
PTC Therapeutics PTCTTakeoverPTC agrees to buy Sangamo's Fabry gene therapy ST-920 in bankruptcy
Arbutus Biopharma ABUSTakeoverArbutus Biopharma starts tender offer for up to US$230 million of its shares
Elutia ELUTOther dealElutia completes SimpliDerm business sale to Cellution Biologics, receives $7.7 million
Arbutus Biopharma ABUSTakeoverArbutus plans US$230 million Dutch auction tender offer for its shares
Baxter International BAXTakeoverBaxter raises note tender offer cap to $600 million after early results
ENDRA Life Sciences, ASP Isotopes NDRAASPIOther dealENDRA reports second quarter 2026 results and merger progress
Fulcrum Therapeutics FULCOther dealFulcrum Therapeutics agrees to all-stock merger with Slate Medicines
Bio Green Med Solution BGMSOther dealBio Green Med reports second-quarter results and updates Future NRG deal
Tarsus Pharmaceuticals TARSTakeoverTarsus agrees to buy Alkeus for $270,000,000 in cash and $180,000,000 in stock
Ensysce Biosciences ENSCAsset sale or purchaseEnsysce Biosciences buys Cy Biopharma, agrees to two-tranche private placement of Series C stock
Eton Pharmaceuticals ETONOther dealEton Pharmaceuticals licenses ASN-001 from Auson for $3.0 million upfront
LogicMark LGMKOther dealLogicMark agrees to $1.31 per share cash merger with Langham Project
Lisata Therapeutics LSTATakeoverLisata cuts 72% of staff after failed Kuva buyout, then merges with Marea
SYNLOGIC, INC. SYBXOther dealSynlogic to merge with Caldera Therapeutics in all-stock deal
Processa Pharmaceuticals PCSAOther dealProcessa acquires Vidya Therapeutics with $200 million placement
FOXO TECHNOLOGIES INC. FOXOTakeoverVector BioSource agrees to buy four blood collection centers
TRAFALGAR INTERNATIONAL, INC. GCANDOther dealTrafalgar adds three new officers and three incoming directors
Neuphoria Therapeutics, Scancell Holdings Plc NEUPSCLPOther dealNeuphoria and Scancell agree to all-share merger with up to $89 million financing
Senti Biosciences Holdings SNTIOther dealSenti Biosciences signs merger agreement with Celadon affiliate, with CVRs tied to SENTI-202
NextCure NXTCOther dealNextCure signs merger agreement with Avere Therapeutics alongside $320 million private placement
Matinas Biopharma Holdings MTNBOther dealMatinas plans GH Power combination and sells MAT2203 to Azurity
MacroGenics MGNXAsset sale or purchaseMacroGenics completes sale of CDMO manufacturing business to Bora for $122.5 million
MacroGenics MGNXAsset sale or purchaseMacroGenics completes sale of manufacturing operations to Bora for $122.5 million
NOMAD POWER SOLUTIONS, INC. NMADOther dealLIXTE completes merger with NOMAD Transportable Power Systems
Cumberland Pharmaceuticals CPIXOther dealCumberland Pharmaceuticals closes $100 million asset sale to Apotex affiliates
Cumberland Pharmaceuticals CPIXOther dealCumberland Pharmaceuticals closes $100 million branded-product deal with Apotex
Zymeworks ZYMETakeoverZymeworks agrees to buy Theravance Biopharma for $17 per share, about $929 million
Rigel Pharmaceuticals RIGLOther dealRigel Pharmaceuticals completes vepdegestrant license, pays $70.0 million upfront
Rigel Pharmaceuticals RIGLOther dealRigel completes vepdegestrant license from Arvinas and Pfizer, pays $70.0 million
Prestige Consumer Healthcare PBHOther dealPrestige Consumer Healthcare closes $1.045 billion Breathe Right acquisition, signs new term loan
Rocket Pharmaceuticals RCKTAsset sale or purchaseRocket Pharmaceuticals closes $180 million sale of priority review voucher
Adial Pharmaceuticals ADILOther dealAdial acquires Azora Therapeutics and announces up to $64 million financing
Veraxa Biotech VRXAOther dealVeraxa Biotech closes Voyager SPAC merger, Nasdaq trading starts June 11
Aditxt ADTXOther dealAditxt signs deal to take Ignite Proteomics public at $150 million value
Bio Green Med Solution BGMSTakeoverBio Green Med agrees to all-stock deal to acquire Future NRG
CONMED CNMDTakeoverCONMED agrees to buy back 2.250% convertible notes due 2027 for cash
REGENXBIO RGNXOther dealREGENXBIO starts stock option exchange offer for non-executive employees
REGENXBIO RGNXOther dealREGENXBIO starts stock option exchange for non-executive employees
OSR Health OSRHTakeoverOSR Health agrees to buy VXM01 assets from Vaximm for $30,000,000
InMed Pharmaceuticals INMOther dealInMed agrees to all-stock merger with Mentari Therapeutics
Parabilis Medicines PBLSTakeoverParabilis Medicines files for IPO; Regeneron agrees to buy about $75.0 million of stock
HEALTHY EXTRACTS INC. HYEXOther dealHealthy Extracts acquires Adli Gummies, which does business as Imaraïs Beauty
Cumberland Pharmaceuticals CPIXAsset sale or purchaseCumberland Pharmaceuticals files proxy for $100 million asset sale to Apotex
Collegium Pharmaceutical COLLOther dealCollegium completes $650 million AZSTARYS acquisition, funded with cash and $300 million term loan
Collegium Pharmaceutical COLLOther dealCollegium completes AZSTARYS purchase for about $650 million, raises 2026 guidance
Aurinia Pharmaceuticals AUPHTakeoverAurinia completes Kezar Life Sciences acquisition after tender offer at $6.955 per share plus CVR
Lisata Therapeutics LSTATakeoverLisata and Kuva Labs delay tender offer start to May 29, Kuva to pay up to $1.1 million of expenses
Aura Biosciences AURAOther dealAura Biosciences agrees to repurchase Matrix Capital's 6,922,870 shares at $5.64 offering price
Gyre Therapeutics GYREOther dealGyre Therapeutics completes all-stock acquisition of Cullgen valued at about $300 million
Rallybio RLYBDeal endedRallybio to receive $50,000,000 fee after Candid ends merger
Shuttle Pharmaceuticals Holdings SHPHOther dealShuttle Pharmaceuticals agrees to merge with United Dogecoin
Senti Biosciences Holdings SNTIDeal endedSenti Biosciences agrees to sell $10.0 million of secured convertible notes to Celadon affiliate
Perrigo Company PRGOAsset sale or purchasePerrigo completes sale of Dermacosmetics business to Karo for €305.6 million in cash
Avalo Therapeutics AVTXOther dealAvalo Therapeutics agrees to pay $2.25 million for option on $15 million AlmataBio milestone
Ligand Pharmaceuticals LGNDTakeoverLigand Pharmaceuticals signs merger agreement to acquire XOMA Royalty for $39.00 per share in cash
Organon & Co. OGNOther dealOrganon agrees to be acquired by Sun Pharma for $14.00 per share in cash
Telomir Pharmaceuticals TELOOther dealTelomir Pharmaceuticals completes acquisition of TELI Pharmaceuticals for 34,389,710 shares
Obsidian Therapeutics OBXOther dealGalera and Obsidian Therapeutics merger moves forward with Gazelle Parent S-4
First Tracks Biotherapeutics TRAXOther dealFirst Tracks Biotherapeutics begins Nasdaq trading after AnaptysBio spin-off
AnaptysBio ANABOther dealAnaptysBio completes spin-off of First Tracks Biotherapeutics, keeps royalty business
AnaptysBio, First Tracks Biotherapeutics ANABTRAXOther dealAnaptysBio completes spin-off of First Tracks Biotherapeutics
First Tracks Biotherapeutics TRAXOther dealFirst Tracks Biotherapeutics begins Nasdaq trading as TRAX with $180 million in cash
MeiraGTx Holdings MGTXAsset sale or purchaseMeiraGTx buys XLRP gene therapy rights from Janssen for $25,000,000 upfront
MeiraGTx Holdings MGTXTakeoverMeiraGTx agrees to buy bota-vec from Johnson & Johnson for $25 million upfront
Wave Life Sciences WVEOther dealWave Life Sciences plans to move its parent company from Singapore to Delaware
Supernus Pharmaceuticals SUPNOther dealSupernus acquires Navitor's NV-5138 assets for a study pledge and up to $350 million in milestones
Northwest Biotherapeutics NWBOOther dealNorthwest Biotherapeutics reports October 2025 closing of Advent BioServices purchase
Lisata Therapeutics LSTATakeoverLisata and Kuva Labs push back tender offer start to April 13, 2026
Aurinia Pharmaceuticals AUPHTakeoverAurinia unit agrees to acquire Kezar Life Sciences in tender offer at $6.955 per share plus a CVR
Korsana Biosciences KRSAOther dealCyclerion (now Korsana Biosciences) agrees to all-stock merger with Korsana, $380 million financing
Oramed Pharmaceuticals ORMPAsset sale or purchaseOramed closes Oratech sale to Lifeward for shares, warrants and revenue share
SCYNEXIS SCYXOther dealSCYNEXIS acquires Poxel's PXL-770 for $8,000,000 upfront and up to $188,000,000 in milestones
Indaptus Therapeutics INDPOther dealIndaptus Therapeutics reports change in control as Lazar sells preferred stock for $11,200,000
Lakefront Biotherapeutics LKFTOther dealGalapagos (now Lakefront Biotherapeutics) in advanced talks with Gilead on Ouro program
SciSparc, NeuroThera Labs SPRCNTLXOther dealSciSparc unit NeuroThera Labs to buy 54.01% of CliniQuantum for shares
Indaptus Therapeutics INDPOther dealIndaptus stockholders approve preferred stock conversion and reverse split range
Atrium Therapeutics RNAOther dealAtrium Therapeutics completes spin-off from Avidity Biosciences, starts trading on Nasdaq as RNA
Atrium Therapeutics RNADeal endedAtrium Therapeutics spin-off from Avidity to give holders one share per ten
Faeth Therapeutics FTHOther dealSensei Biotherapeutics acquires Faeth Therapeutics, agrees to $200 million private placement
Nutriband NTRBAsset sale or purchaseNutriband terminates planned $5 million sale of Pocono unit
Indivior Pharmaceuticals INDVOther dealIndivior PLC (now Indivior Pharmaceuticals, Inc.) completes U.S. domestication
Agenus AGENDeal endedAgenus completes $75.0 million manufacturing asset sale to Zydus and $16.0 million stock sale
SL Science Holding SLBTOther dealSL Science Holding files F-4 for Horizon Space Acquisition II and SL BIO merger
Valion Bio VBIOAsset sale or purchaseTivic Health Systems (now Valion Bio) buys Scorpius CDMO assets for $16,253,147.10
Natera NTRAOther dealNatera closes Foresight Diagnostics acquisition, agrees to issue 1,127,982 shares
Baxter International BAXTakeoverBaxter closes three-series senior notes offering with about $1.99 billion in net proceeds
Omeros OMEROther dealOmeros closes zaltenibart sale to Novo Nordisk, receives $240.0 million and repays term loan
Q32 Bio, Akebia Therapeutics QTTBAKBAOther dealQ32 Bio sells ADX-097 to Akebia Therapeutics for $7.0 million upfront
Abbott Laboratories ABTTakeoverAbbott agrees to acquire Exact Sciences for $105 per share in cash, about $21 billion
Harrow HROWOther dealHarrow completes Melt Pharmaceuticals acquisition with approximately $4.3 million paid at closing
Bristol-Myers Squibb BMYTakeoverBristol Myers Squibb amends cash tender offers and sets early settlement for November 20
IGC Pharma IGCOther dealIGC Pharma subsidiary closes Vancouver facility asset sale valued at about $2.7 million
IGC Pharma IGCOther dealIGC Pharma unit sold Vancouver facility assets for supply rights, not cash
Damora Therapeutics DMRAAsset sale or purchaseGalecto (now Damora Therapeutics) buys Damora, agrees to about $285 million private placement
Biofrontera BFRIDeal endedBiofrontera sells Xepi cream assets to Pelthos Therapeutics, gets $3 million at closing
Absci ABSIOther dealAbsci and Totient sellers agree final milestone payout under 2021 merger agreement
Calidi Biotherapeutics CLDIOther dealCalidi Biotherapeutics sells 75% Nova Cell stake for $6,000,000, mostly deferred and contingent
Biofrontera BFRIOther dealBiofrontera Inc. closes purchase of U.S. Ameluz and RhodoLED rights, sells $2.5 million preferred
Alkermes ALKSTakeoverAlkermes agrees to buy Avadel for $18.50 a share plus CVR, with JPMorgan bridge loan
BioNTech BNTXOther dealBioNTech opens exchange offer for CureVac with 15,061,575 new ADSs registered
Keros Therapeutics KROSTakeoverKeros Therapeutics starts tender offer for up to 10,950,165 shares at $17.75
Keros Therapeutics KROSTakeoverKeros Therapeutics to repurchase 10,176,595 shares for about $181 million, plans tender offer
Keros Therapeutics KROSTakeoverKeros agrees to buy back ADAR1 and Pontifax shares at $17.75, plans tender offer
TransCode Therapeutics RNAZTakeoverTransCode agrees to buy Polynoma and sell CK Life Sciences $25 million of preferred stock
Elutia ELUTOther dealElutia closes CIED business sale to Boston Scientific, puts $8 million in escrow, repays SWK loan
Elutia, BOSTON SCIENTIFIC CORP ELUTBSXAsset sale or purchaseElutia closes $88 million sale of BioEnvelope business to Boston Scientific
GridAI Technologies GRDXOther dealEntero Therapeutics (now GridAI Technologies) acquires GRID AI, whose holders get 82.5%
Halozyme Therapeutics HALOTakeoverHalozyme signs merger agreement to acquire Elektrofi for $750 million in cash upfront
MIRA Pharmaceuticals MIRAOther dealMIRA Pharmaceuticals closes SKNY acquisition in all-stock deal
Traws Pharma TRAWAsset sale or purchaseTraws Pharma buys antiviral compound assets from related party Viriom for $2,350,000 cash
NRX Pharmaceuticals NRXPOther dealNRx Pharmaceuticals completes acquisition of Dura Medical clinics through HOPE unit
Traws Pharma TRAWAsset sale or purchaseTraws Pharma buys antiviral assets from Viriom for $2,350,000 in related-party deal
Bausch Health Companies BHCTakeoverBausch Health completes DURECT acquisition after tender offer draws about 62% of shares
Pharvaris PHVSOther dealPharvaris signs registration rights agreement with General Atlantic PH B.V.
Kyntra Bio KYNBOther dealFibroGen (now Kyntra Bio) completes $220 million China unit sale to AstraZeneca
PharmaCyte Biotech PMCBOther dealPharmaCyte Biotech adds $3 million to its stake in TNF Pharmaceuticals
Medicus Pharma MDCXOther dealMedicus Pharma completes Antev acquisition for about US$3.0 million cash and 1,603,164 shares
CorMedix CRMDOther dealCorMedix completes Melinta Therapeutics acquisition for $300 million in upfront consideration
Zenas BioPharma, Royalty Pharma ZBIORPRXOther dealZenas BioPharma signs Royalty Pharma funding deal worth up to $300 million
Evofem Biosciences EVFMOther dealEvofem signs sixth amendment to Aditxt merger agreement
Heron Therapeutics HRTXOther dealHeron Therapeutics adopts rights plan with 4.99% trigger to protect tax losses
Heron Therapeutics HRTXOther dealHeron Therapeutics adopts rights plan to protect $1.37 billion of tax losses
BridgeBio Oncology Therapeutics BBOTOther dealHelix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) completes business combination
PTC Therapeutics PTCTOther dealPTC Therapeutics pays about $225.0 million to cancel Censa sepiapterin sales payment rights
CorMedix CRMDOther dealCorMedix to buy Melinta Therapeutics, closing targeted as early as September 1
PTC Therapeutics PTCTOther dealPTC Therapeutics pays about $225.0 million to cancel Censa sales payments
NeOnc Technologies Holdings NTHIDeal endedNeOnc Technologies signs up to $50 million investment deal with Quazar at $25 per share
Supernus Pharmaceuticals SUPNTakeoverSupernus completes Sage Therapeutics acquisition after tender offer, $8.50 per share plus CVR
Adaptimmune Therapeutics ADAPYOther dealAdaptimmune sells cell therapy assets to US WorldMeds for $55 million upfront
Veraxa Biotech VRXAOther dealVeraxa Biotech Holding AG (now Veraxa Biotech AG) files F-4 for Voyager SPAC deal
ImageneBio IMAOther dealIkena Oncology (now ImageneBio) completes Inmagene merger, issues contingent value rights
ImageneBio IMAOther dealImageneBio says Ikena Oncology and Imagene merger completed in July 2025
Lantheus Holdings LNTHOther dealLantheus completes Life Molecular Imaging acquisition with $350 million upfront payment
NovaBridge Biosciences NBPOther dealI-Mab (now NovaBridge Biosciences) to buy Bridge Health Biotech for $1.8 million upfront
Oncopeptides AB ONCOOther dealOnconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%
BridgeBio Oncology Therapeutics, BridgeBio Pharma BBOTBBIOOther dealHelix Acquisition Corp. II (now BridgeBio Oncology Therapeutics) says S-4 is effective, vote set for August 4
Semnur Pharmaceuticals SMNRDeal endedDenali Capital (now Semnur Pharmaceuticals) extends SPAC deadline to August 11, 2025
Rallybio RLYBOther dealRallybio sells 50% stake in ENPP1 joint venture to Recursion for cash and shares
Rallybio RLYBOther dealRallybio sells ENPP1 joint venture stake to Recursion for initial $7,500,000 in stock
Pelthos Therapeutics PTHSOther dealChannel Therapeutics (now Pelthos Therapeutics) closes merger and $50.1 million private placement
Abeona Therapeutics ABEOAsset sale or purchaseAbeona Therapeutics closes $155 million sale of priority review voucher
Pelthos Therapeutics PTHSOther dealChannel Therapeutics (now Pelthos) sets 10-for-one reverse split ahead of merger
ImageneBio IMAOther dealIkena Oncology (now ImageneBio) files merger partner Inmagene's Phase 2b trial start
TuHURA Biosciences HURAOther dealTuHURA Biosciences completes Kineta acquisition, paying 0.185298 TuHURA share per Kineta share
TuHURA Biosciences HURAOther dealTuHURA Biosciences completes acquisition of Kineta in all-stock deal
Medicus Pharma MDCXTakeoverMedicus Pharma agrees to buy Antev for 2,666,600 shares plus up to US$65 million
Impact BioMedical IBOReverse mergerImpact BioMedical signs reverse merger agreement with Dr Ashleys Limited
Impact BioMedical IBOReverse mergerImpact BioMedical agrees to reverse merger with Hong Kong drugmaker Dr Ashleys
Ocugen, Carisma Therapeutics OCGNCARMOther dealOcugen unit OrthoCellix to merge with Carisma alongside planned $25.0 million financing
Viskase Holdings VISKOther dealEnzon Pharmaceuticals (now Viskase Holdings) agrees all-stock merger with Viskase
Crescent Biopharma CBIOOther dealGlycoMimetics (now Crescent Biopharma) completes merger and $200 million private financing
Decoy Therapeutics DCOYOther dealSalarius (now Decoy Therapeutics) cuts its valuation to $2.31 million in merger deal
Aytu BioPharma AYTUOther dealAytu BioPharma signs EXXUA commercialization deal with Fabre-Kramer, pays $3,000,000 upfront
Aytu BioPharma AYTUOther dealAytu BioPharma pays $3,000,000 upfront for U.S. rights to depression drug EXXUA
Fortress Biotech FBIOOther dealFortress Biotech to receive about $28.0 million as Checkpoint merger with Sun Pharma closes
Fortress Biotech FBIOAsset sale or purchaseFortress Biotech to receive about $28.0 million as Checkpoint sale to Sun Pharma closes
Alto Neuroscience ANROAsset sale or purchaseAlto Neuroscience buys depression drug candidates from Chase Therapeutics, pays $1,750,000 upfront
Alumis ALMSDeal endedAlumis completes ACELYRIN merger at 0.4814 Alumis shares per ACELYRIN share
Alumis ALMSOther dealAlumis completes merger with ACELYRIN at 0.4814 shares per ACELYRIN share
Royalty Pharma RPRXOther dealRoyalty Pharma completes acquisition of RP LLC for $200,000,000 cash and 24,530,266 Class E shares
Protagenic Therapeutics PTIXOther dealProtagenic Therapeutics combines with Phytanix Bio in all-stock deal
Pulmatrix PULMAsset sale or purchasePulmatrix says Cullgen merger registration is effective, plans to divest assets
Pulmatrix PULMOther dealPulmatrix says Cullgen merger filing is effective, expects June 2025 close
Jade Biosciences JBIOOther dealJade Biosciences files Q1 financials after Aerovate merger and $334.2 million financing
Jade Biosciences JBIOOther dealJade Biosciences (formerly Aerovate) details $334.2 million pre-merger financing
Jade Biosciences JBIOOther dealAerovate Therapeutics (now Jade Biosciences) completes merger and private placement
Avenue Therapeutics ATXIDeal endedAvenue Therapeutics ends AJ201 license and transfers program back to AnnJi
TriSalus Life Sciences TLSIOther dealTriSalus agrees to sell 5,500,000 shares at $4.00 in $22.0 million private placement
Jazz Pharmaceuticals JAZZTakeoverJazz Pharmaceuticals completes acquisition of Chimerix for about $935 million in cash
Scilex Holding SCLXDeal endedScilex unit Semnur amends Denali merger deal, moves outside date to September 30, 2025
Tvardi Therapeutics TVRDOther dealCara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split
OS Therapies OSTXOther dealOS Therapies completes purchase of Advaxis immunotherapy assets from Ayala
Coherus Oncology CHRSOther dealCoherus BioSciences (now Coherus Oncology) completes UDENYCA sale, gets $483.4 million upfront
Coherus Oncology CHRSOther dealCoherus (now Coherus Oncology) completes UDENYCA sale to Intas for $483.4 million upfront
Pulmatrix PULMOther dealPulmatrix and Cullgen amend merger agreement, switching to a one-step merger
Pulmatrix PULMDeal endedPulmatrix amends Cullgen merger agreement to a one-step merger
Zevra Therapeutics ZVRAAsset sale or purchaseZevra Therapeutics closes $150 million sale of rare pediatric disease priority review voucher
Lantheus Holdings LNTHOther dealLantheus completes Evergreen Theragnostics acquisition, paying about $275 million in cash
Tvardi Therapeutics TVRDOther dealCara Therapeutics (now Tvardi Therapeutics) stockholders approve Tvardi merger share issuance
ProKidney PROKOther dealProKidney files to move incorporation from the Cayman Islands to Delaware
Kyntra Bio KYNBDeal endedFibroGen (now Kyntra Bio) extends Fortis merger option deadline to December 31, 2027
Whitehawk Therapeutics WHWKAsset sale or purchaseWhitehawk Therapeutics (formerly Aadi Bioscience) completes $102.4 million sale of Aadi Subsidiary
Whitehawk Therapeutics WHWKAsset sale or purchaseWhitehawk Therapeutics completes sale of Aadi Subsidiary to Kaken for $102.4 million
GridAI Technologies GRDXOther dealEntero (now GridAI Technologies) signs deal to unwind ImmunogenX merger
Bausch Health Companies BHCOther dealBausch Health launches $4.0 billion senior secured notes offering to refinance debt
Kalaris Therapeutics KLRSOther dealAlloVir (now Kalaris Therapeutics) completes Kalaris merger; shares to trade as KLRS on March 19
Kalaris Therapeutics KLRSOther dealKalaris Therapeutics closes merger with AlloVir; stock trades as KLRS from March 19, 2025
Pliant Therapeutics PLRXOther dealPliant Therapeutics, Inc. adopts stockholder rights plan with $12.64 exercise price
Pliant Therapeutics PLRXOther dealPliant Therapeutics adopts one-year shareholder rights plan after stock buildup
Kalaris Therapeutics KLRSOther dealAlloVir (now Kalaris Therapeutics) stockholders approve Kalaris merger and change of control
Kalaris Therapeutics KLRSOther dealAlloVir (now Kalaris Therapeutics) stockholders approve merger with Kalaris
Anika Therapeutics ANIKAsset sale or purchaseAnika Therapeutics sells Parcus Medical to Medacta for $4,500,000 in cash
Anika Therapeutics ANIKAsset sale or purchaseAnika Therapeutics completes sale of Parcus Medical to Medacta Group
Fortress Biotech FBIOOther dealFortress Biotech's Checkpoint unit agrees to Sun Pharma deal at $4.10 a share plus CVR
Jazz Pharmaceuticals JAZZTakeoverJazz Pharmaceuticals agrees to acquire Chimerix for $8.55 per share in cash
Jade Biosciences JBIOOther dealAerovate Therapeutics (now Jade Biosciences) files merger material from Jade
Mustang Bio MBIOOther dealMustang Bio sells Worcester equipment to AbbVie for $1.0 million and exits facility lease
Crescent Biopharma CBIOReverse mergerCrescent still expects GlycoMimetics reverse merger to close in second quarter of 2025
Mustang Bio MBIOOther dealMustang Bio sells fixed assets to AbbVie for $1.0 million and exits Worcester facility
PRF Technologies PRFXTakeoverPainReform (now PRF Technologies) agrees to buy DeepSolar business for shares and warrants
Alumis ALMSOther dealAlumis agrees to all-stock merger with ACELYRIN, with pro forma cash of about $737 million
Alumis ALMSOther dealAlumis and ACELYRIN agree to all-stock merger with $737 million pro forma cash
Baxter International BAXAsset sale or purchaseBaxter completes Kidney Care business sale and receives about $3.71 billion in net cash proceeds
Whitehawk Therapeutics WHWKAsset sale or purchaseAadi Bioscience (now Whitehawk Therapeutics) seeks vote on $100 million FYARRO sale
Coherus Oncology CHRSDeal endedCoherus BioSciences (now Coherus Oncology) seeks vote on $483.4 million UDENYCA sale
Lunai Bioworks LNAIOther dealRenovaro (now Lunai Bioworks) signs binding letter to buy Predictive Oncology
Bio Green Med Solution BGMSOther dealCyclacel (now Bio Green Med Solution) agrees to sell $3.1 million of preferred stock
Eton Pharmaceuticals ETONOther dealEton Pharmaceuticals completes acquisition of Galzin from Teva for $7.0 million at closing
Aspire-Lakewood Holdings ASBPOther dealPowerUp Acquisition (now Aspire-Lakewood) gets loan of up to $500,000 before merger
Serina Therapeutics SERAsset sale or purchaseSerina Therapeutics sells UniverXome to Juvenescence, which takes on $11.2 million of debt
Tvardi Therapeutics TVRDDeal endedCara Therapeutics (now Tvardi Therapeutics) agrees all-stock merger with private Tvardi
Neuphoria Therapeutics NEUPOther dealBionomics (now Neuphoria Therapeutics) wins court approval for its US move
Nektar Therapeutics NKTRAsset sale or purchaseNektar completes sale of Huntsville, Alabama plant to Ampersand affiliate
TuHURA Biosciences HURATakeoverTuHURA Biosciences signs letter of intent to acquire Kineta's KVA12123
Akari Therapeutics Plc AKTXOther dealAkari Therapeutics shareholders approve share issuance for Peak Bio merger
Geron GERNOther dealGeron completes $250 million Royalty Pharma and Pharmakon financings
Palvella Therapeutics PVLAOther dealPieris (now Palvella Therapeutics) files merger partner's Phase 3 dosing news
MindMaze Therapeutics Holding SA MMTXReverse mergerRelief Therapeutics (now MindMaze) signs non-binding LOI for Renexxion reverse merger
Lyell Immunopharma LYELOther dealLyell Immunopharma completes acquisition of ImmPACT Bio
Immunome IMNMAsset sale or purchaseImmunome buys licensed Zentalis ROR1 assets for 1,805,502 shares
OSR Health OSRHDeal endedBellevue Life Sciences Acquisition (now OSR Health) lends $300,000 to OSR Holdings

How this tracker works

We add a deal when a merger agreement, tender offer, S-4, proxy or closing is filed with the SEC or announced by the company. Ownership splits are the ones the filing states. Every row links our story, and every story links the filing, court record or release it is based on. Something missing or wrong? Tell the editors.

News, not investment advice. How we work.

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.